NOVARTIS AG-SPONSORED ADR (NVS) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:NVS - US66987V1098 - ADR
141.98 USD
-0.29 (-0.2%)
141.3 USD
-0.68 (-0.48%)
ChartMill assigns a Buy % Consensus number of 70% to NVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 135.04. This target is -4.89% below the current price.
NVS was analyzed by 31 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about NVS.
In the previous month the buy percentage consensus was at a similar level.
NVS was analyzed by 31 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-06 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-12-08 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-09-12 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2025-02-13 | UBS | Downgrade | Buy -> Neutral |
| 2024-11-19 | Erste Group | Downgrade | Buy -> Hold |
| 2024-10-30 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-09-11 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-09-05 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-09-03 | Jefferies | Downgrade | Buy -> Hold |
| 2024-07-02 | Jefferies | Maintains | Buy -> Buy |
| 2024-04-24 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-02-23 | BMO Capital | Initiate | Market Perform |
| 2024-01-23 | Morgan Stanley | Initiate | Equal-Weight |
| 2023-09-25 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2022-05-09 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2021-12-06 | Exane BNP Paribas | Downgrade | Outperform -> Neutral |
| 2021-12-03 | Bryan Garnier | Downgrade | Buy -> Neutral |
| 2021-09-20 | Deutsche Bank | Downgrade | Hold -> Sell |
NOVARTIS AG-SPONSORED ADR / NVS FAQ
What is the average price target for NOVARTIS AG-SPONSORED ADR (NVS) stock?
31 analysts have analysed NVS and the average price target is 135.04 USD. This implies a price decrease of -4.89% is expected in the next year compared to the current price of 141.98.
What is the consensus rating for NVS stock?
The consensus rating for NOVARTIS AG-SPONSORED ADR (NVS) is 70.3226 / 100 . This indicates that analysts generally have a positive outlook on the stock.